Tumor LAG‐3 and NY‐ESO‐1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non‐small cell lung cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) are an established treatment for non‐small cell lung cancer (NSCLC) that have demonstrated durable clinical benefits (DCBs). Previous studies have suggested NY‐ESO‐1 and LAG‐3 to be surrogate markers of ICI responses in NSCLC; therefore, we explored th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Jung, Eun Hee, Jang, Hee Ryeong, Kim, Se Hyun, Suh, Koung Jin, Kim, Yu Jung, Lee, Ju‐Hyun, Chung, Jin‐Haeng, Kim, Miso, Keam, Bhumsuk, Kim, Tae Min, Kim, Dong‐Wan, Heo, Dae Seog, Lee, Jong Seok
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2021
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7919166/
https://ncbi.nlm.nih.gov/pubmed/33458968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13834
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados